Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non Operating Income (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Non Operating Income for 4 consecutive years, with -$1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 149.4% to -$1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.2 million, a 182.68% decrease, with the full-year FY2024 number at -$1.7 million, up 68.92% from a year prior.
  • Non Operating Income was -$1.8 million for Q3 2025 at Centessa Pharmaceuticals, down from $3.6 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.4 million in Q2 2022 to a low of -$4.0 million in Q4 2024.
  • A 4-year average of -$131000.0 and a median of -$878000.0 in 2023 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: crashed 1154.29% in 2023, then surged 2232.47% in 2025.
  • Centessa Pharmaceuticals' Non Operating Income stood at -$70000.0 in 2022, then plummeted by 1154.29% to -$878000.0 in 2023, then plummeted by 351.94% to -$4.0 million in 2024, then soared by 54.39% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Non Operating Income are -$1.8 million (Q3 2025), $3.6 million (Q2 2025), and $1.0 million (Q1 2025).